user

10 YEARS OF AMNOG: IMPORTANCE OF REAL-WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT PROCESS

被引：0
|
作者：
Seidel, K. [1 ]
Schnaidt, S. [1 ]
Viering, T. [1 ]
Loepmeier, J. F. [1 ]
Borchert, K. [1 ]
Jacob, C. [1 ]
机构：
[1] Xcenda GmbH, Hannover, NI, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA92
引用
收藏
页码：S314 / S314
页数：1
相关论文
共 50 条
  • [1] THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS
    Borchert, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S795 - S795
  • [2] TRENDS IN THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS 2011-2019
    Borchert, K.
    Seidel, K.
    Loepmeier, J. F.
    Braun, S.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2020, 23 : S666 - S666
  • [3] PREVALENCE AND INCIDENCE ESTIMATIONS IN GERMAN AMNOG APPLICATIONS - THE ROLE OF REAL-WORLD EVIDENCE (RWE)
    Altevers, J.
    Borchert, K.
    Mittendorf, T.
    Braun, S.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A558 - A558
  • [4] USE OF REAL WORLD EVIDENCE IN GERMAN AMNOG APPLICATIONS
    Altevers, J.
    Borchert, K.
    Mittendorf, T.
    Braun, S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A95 - A95
  • [5] REAL WORLD EVIDENCE IN GERMAN HTA: THE CHALLENGES OF COMPARATIVE ROUTINE PRACTICE DATA COLLECTION (ABD) FOR EARLY BENEFIT ASSESSMENT (AMNOG)
    Bogner, K.
    Ebentheuer, L. M.
    Wegener, M.
    Wuetner, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S386 - S386
  • [6] Importance of real-world evidence in German social and health law
    Trute, H. -H.
    [J]. GEFASSCHIRURGIE, 2019, 24 (03): : 228 - 233
  • [7] The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies
    Radawski, Christine A.
    Hammad, Tarek A.
    Colilla, Susan
    Coplan, Paul
    Hornbuckle, Kenneth
    Freeman, Emily
    Smith, Meredith Y.
    Sobel, Rachel E.
    Bahri, Priya
    Arias, Ariel E.
    Bennett, Dimitri
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (12) : 1532 - 1539
  • [8] LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPE
    Konig, C.
    Krinke, K.
    Haas, J. S.
    McLeod, K.
    Braun, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S195 - S195
  • [9] Methods Used for Trend Estimation of Epidemiological Figures in the German Benefit Assessment (AMNOG) Process
    Schnaidt, S.
    Seidel, K.
    Viering, T.
    Loepmeier, J. F.
    Borchert, K.
    Jacob, C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S336 - S336
  • [10] The Increasing Importance of Rigorous Real-World Evidence
    Yang, David D.
    Nguyen, Paul L.
    [J]. JNCI CANCER SPECTRUM, 2022, 6 (04)
12345